Detalhe da pesquisa
1.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
N Engl J Med
; 369(6): 507-16, 2013 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23782157
2.
Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib.
Ann Hematol
; 94(2): 249-56, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25178517
3.
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Blood
; 119(24): 5661-70, 2012 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-22555973
4.
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Br J Haematol
; 158(6): 739-48, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22845873
5.
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
Clin Cancer Res
; 22(23): 5829-5838, 2016 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27189165
6.
Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
J Clin Oncol
; 32(17): 1797-803, 2014 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24799467
7.
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Clin Cancer Res
; 19(8): 2248-56, 2013 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23447001
8.
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Clin Cancer Res
; 18(17): 4830-40, 2012 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22761464
9.
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Clin Lymphoma Myeloma Leuk
; 12(5): 310-8, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23040437
10.
Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma.
Clin Cancer Res
; 16(5): 1673-81, 2010 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20179219
11.
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.
Clin Cancer Res
; 15(22): 7085-91, 2009 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19903785